ARL8B

Across TCGA pan-cancer cohorts, ARL8B RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ARL8B’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ARL8B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARL8B is over-expressed in tumor, although a few such as KIRC and LUAD show the opposite, repressed pattern.

LIHC, KIRC, and BLCA are the cancer types where ARL8B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL8B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+1.032	<.001	9	view →
KIRC	Male	II,III,IV	−0.535	<.001	9	view →
BLCA	All	IV	+0.504	.007	8	view →
BRCA	All	III,IV	+0.522	<.001	6	view →
HNSC	All	All	+0.309	.002	6	view →
LUAD	All	All	−0.223	<.001	5	view →
CHOL	All	All	+0.934	.001	4	view →
KICH	All	All	−0.476	.002	4	view →
UCEC	All	All	−0.457	.001	2	view →
PRAD	All	All	−0.236	.025	2	view →
READ	Female	All	−0.511	.013	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ARL8B–LIHC

Open the LIHC breakdown →